<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02244632</url>
  </required_header>
  <id_info>
    <org_study_id>ISO-CC-005</org_study_id>
    <secondary_id>2014-001862-84</secondary_id>
    <nct_id>NCT02244632</nct_id>
  </id_info>
  <brief_title>Modufolin® in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer</brief_title>
  <official_title>An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin®) in Combination With a Fixed Dose of 5-Fluorouracil (5-FU) Alone or Together With a Fixed Dose of Oxaliplatin or Irinotecan in Patients With Stage IV Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isofol Medical AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isofol Medical AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to characterise the tolerability of Modufolin in combination with 5-FU alone,
      in combination with 5-FU and Oxaliplatin, in combination with 5-FU and Irinotecan and in
      combination with 5-FU, Oxaliplatin and Bevacizumab.

      Another purpose is to investigate 4 doses of Modufolin to identify the best dose for further
      assessment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will investigate the tolerability of Modufolin at four (4) different dose levels
      (30 to 240 mg/m2) in therapy combinations with the chemotherapeutic agents 5-FU, Oxaliplatin
      +/- bevcizumab, and Irinotecan.

      When the selected phase 2 dose is determined, 20 additional patients, will be included in the
      study in order to acquire more data on the safety and tolerability of Modufolin at this dose
      level. Ten (10) of these additional patients will be treated in with Oxaliplatin, 10 with
      Irinotecan.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of dose limiting toxicity (DLT) or other Adverse Events (AE)</measure>
    <time_frame>The patients will be followed during 4 cycles of treatment (8 weeks).</time_frame>
    <description>Primary safety variables will consist of monitoring and recording of DLTs and any significant AE that have led to adjustments in the therapy administration.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Colorectal Neoplasm</condition>
  <arm_group>
    <arm_group_label>Modufolin / Nordic FLV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modufolin in combination with 5-Fluorouracil only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modufolin / Nordic FLOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to Nordic FLOX regime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modufolin / Nordic FLIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modufolin in combination with 5-Fluorouracil and Irinotecan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to mFOLFOX-6 regime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOFOX / Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modufolin in combination with 5-Fluorouracil, Oxaliplatin and Bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modufolin in combination with 5-Fluorouracil and Irinotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modufolin</intervention_name>
    <description>IV injection every second week for 8 weeks.</description>
    <arm_group_label>Modufolin / Nordic FLV</arm_group_label>
    <arm_group_label>Modufolin / Nordic FLOX</arm_group_label>
    <arm_group_label>Modufolin / Nordic FLIRI</arm_group_label>
    <arm_group_label>MOFOX</arm_group_label>
    <arm_group_label>MOFOX / Bevacizumab</arm_group_label>
    <arm_group_label>MOFIRI</arm_group_label>
    <other_name>[6R] 5,10-methylenetetrahydrofolate</other_name>
    <other_name>6R-MTHF</other_name>
    <other_name>6R-methylene THF</other_name>
    <other_name>ISO-901</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>IV injection every second week for 8 weeks.</description>
    <arm_group_label>Modufolin / Nordic FLV</arm_group_label>
    <arm_group_label>Modufolin / Nordic FLOX</arm_group_label>
    <arm_group_label>Modufolin / Nordic FLIRI</arm_group_label>
    <arm_group_label>MOFOX</arm_group_label>
    <arm_group_label>MOFOX / Bevacizumab</arm_group_label>
    <arm_group_label>MOFIRI</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>5-Flourouacil</other_name>
    <other_name>5-Fluoro-1H,3H-pyrimidine-2,4-dione</other_name>
    <other_name>Adrucil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>IV infusion every second week for 8 weeks.</description>
    <arm_group_label>Modufolin / Nordic FLOX</arm_group_label>
    <arm_group_label>MOFOX</arm_group_label>
    <arm_group_label>MOFOX / Bevacizumab</arm_group_label>
    <other_name>Eloxatin</other_name>
    <other_name>[(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O')platinum(II)</other_name>
    <other_name>Olatin</other_name>
    <other_name>Oxamed</other_name>
    <other_name>Oxitropic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>IV infusion every second week for 8 weeks.</description>
    <arm_group_label>Modufolin / Nordic FLIRI</arm_group_label>
    <arm_group_label>MOFIRI</arm_group_label>
    <other_name>(+)-(4S)-4,11-Dietyl-4-hydroxi-9-[(4-piperidinopiperidino)karbonyloxi]-1H-pyrano[3¢,4¢:6,7]indolizino[1,2-b]kinolin-3,14-(4H,12H)dion</other_name>
    <other_name>Irinosor</other_name>
    <other_name>Campto</other_name>
    <other_name>Namedica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV infusion every second week for 8 weeks.</description>
    <arm_group_label>MOFOX / Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Advanced metastatic colorectal (Stage IV) cancer verified by biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Göran Carlsson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Skintemo</last_name>
    <phone>+46 (0) 702 43 37 65</phone>
    <email>lisa.skintemo@isofolmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>251 General Airforce Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IASO General Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical School University of Athens, Aretaieio Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Genral Hospital Attikon</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Iráklion</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>461 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Göran Carlsson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Göran Carlsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skaraborg hospital</name>
      <address>
        <city>Skövde</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Greece</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>September 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Colorectal carcinoma</keyword>
  <keyword>Colorectal tumors</keyword>
  <keyword>Intestinal Neoplasm</keyword>
  <keyword>Gastrointestinal Neoplasm</keyword>
  <keyword>Gastrointestinal disease</keyword>
  <keyword>5,10-methylenetetrahydrofolate</keyword>
  <keyword>Tetrahydrofolates</keyword>
  <keyword>Therapeutic uses</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety assessments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Tetrahydrofolates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

